MONTPELLIER, France– SeqOne Genomics, today announced that Michael Blum, Ph.D. is joining the company to lead its research and development department. He is tasked with driving SeqOne’s R&D strategy notably in the area of rare diseases and oncology through the use of machine learning and data science.
Michael started his career as a biostatistician and bioinformatician at the CNRS where he developed software solutions that enabled complex genomic data analysis for biologists and clinicians. He then set up the Grenoble Data Institute, a cross-disciplinary research group, to study how digital technology and data could be harnessed to benefit science and society. In 2019, he joined Owkin where, for the past three years, he has developed AI-based solutions to optimize clinical trials.
At SeqOne, Michael will lead scientific research and the development of new genomic analysis solutions to improve the clinical interpretation and diagnosis of cancer and hereditary diseases. Michael Blum has co-authored over 50 scientific publications, many of which are the fruit of international collaborations in the fields of population genomics and genomic medicine.
Michael holds an engineering degree from Grenoble INP, a PhD in applied mathematics, and completed a post-doctorate in bioinformatics at the University of Michigan.
“SeqOne has developed an impressive set of ground-breaking technologies built on hard science”, said Michael Blum. “We share the same vision that aims to advance personalised medicine by creating a tight interaction between technology and medicine. I am honoured to be part of SeqOne’s management team, leading research initiatives to develop ever more effective diagnostic solutions that will accelerate access to personalized medicine for all patients.”
“Our whole team is delighted that Michael is joining us”, commented Nicolas Philippe, CEO and co-founder of SeqOne Genomics. “His vast expertise in data science and biology represents an extraordinary asset for the development of our international program to develop clinical genomic analysis solutions. His commitment to advancing and spreading knowledge will help extend our leadership among the key players in personalized genomic medicine.”
